Cadila Healthcare Limited

Zydus Lifesciences Limited

Kumar Kamlesh Singh

Nikhil Amar Singh

Shriprakash Dhar Dwivedi

Brij Khera

Shri Prakash Dhar Dwivedi

Jitendra Maganbhai Gajera

Sanjay Jagdish Desai

Kuldeep Natwarlal Jain

Ganpat Dan Shimbhu Charan

Santosh Devidas Diwakar

Sunil Dnyaneshwar Narode

Chetan Jayantibhai Vasava

Amol Kashinath Patil

Nimeshkumar Mukeshkumar Shah

Ashok Prasad

Piyush Rajendra Sharma

Daya Ram Pal

Kirtipalsinh Sajjansinh Solanki

Dhaval Jashvantbhai Patel

Sandip Pundlik Khairnar

Ganapatdan Shimbhu Charan

Dipakkumar Dhanjibhai Vachhani

Hiteshkumar Natwarlal Suthar

Sumer Singh Chundavat

Ganpatdan Shimbhu Charan

Ganpant Dan Shimbu Charan

Anil Kumar Shivprasad Tiwari

Dinesh Kumar Raikwar

Jitesh Amratlal Desai

Sarvil Dhirajbhai Patel

Sanjeev Kumar Tripathi

Dipak Ambalal Patel

Mayur Ramnikbhai Patel

Prashant Rameshchandra Bhatt

The present invention relates to triaminopyrimidine compound 1, or pharmaceutically acceptable salts thereof, or hydrates, or solvates, or polymorphs, or optically active forms thereof, in solid state forms. The invention also relates to a process for preparation of triaminopyrimidine compound and intermediates thereof. The present invention also relates to a pharmaceutical composition comprising pure triaminopyrimidine compound, useful for preventing or treating malaria.

Process for preparation of triaminopyrimidine compound and intermediates thereof

The present invention relates to a composition comprising high purity pyrrole derivative and method for preparation thereof. The present invention particularly relates to compositions comprising Saroglitazar magnesium having purity of 99.0% or more, and one or more of an aldehyde compound of Formula (II), diketo oxirane compound of Formula (III), hydroxy methyl compound of Formula (IV) or dimer compound of Formula (V), relative to saroglitazar magnesium, each present in an amount of about 0.15% or less, respectively, by weight, when measured by area percentage of HPLC.

Composition comprising high purity pyrrole derivative and method for preparation thereof

The invention relates to process for the preparation of isoxazoline-substituted benzamide compound and intermediates thereof. The invention also relates to process for the preparation of Fluralaner and intermediates thereof.

Process for preparation of isoxazoline substituted benzamide compound

The invention relates to process for the preparation of grapiprant and its intermediates thereof. The invention also relates to grapiprant having a purity 98% or more and compounds of Formula (A), (B), (C) and (D) in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC. The invention also relates to an amorphous form of grapiprant and process for preparation thereof.

Process for preparation of grapiprant

The present invention relates to a process for the preparation of apalutamide. In particular, the present invention relates to a process for the preparation of apalutamide and its intermediates. The present invention also relates to pharmaceutical compositions comprising apalutamide.

Process for preparation of apalutamide

The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Amorphous vortioxetine and salts thereof

A novel crystalline form of rifaximin and process for its preparation are described. A pharmaceutical composition comprising crystalline rifaximin is also described.

Crystalline form of rifaximin and process for its preparation

The present invention relates to an amorphous form of linagliptin and processes for the preparation thereof. The invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of an amorphous form of linagliptin and use of the composition for treatment of diabetes especially type-I or type-II, prediabetes or reduction of glucose tolerance.

Amorphous form of linagliptin and process for preparation thereof

The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist. In particular, the present invention provides a process for the preparation of enzalutamide or its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof.

Process for preparation of androgen receptor antagonist

A crystalline Form N-1 of apixaban substantially free from one or more of: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; or methyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate, relative to apixaban by area percentage of HPLC and having a mean particle size equal to or greater than 100 &#x3bc;m.

Process for the preparation of apixaban

The field of the invention relates to a process for the preparation of amorphous imatinib mesylate. In particular, the invention relates to a process for the preparation of stable amorphous imatinib mesylate. More particularly, the invention relates to pharmaceutical compositions that includes the stable amorphous imatinib messylate together along with its excipients.

Process for the preparation of amorphous imatinib mesylate

The present invention relates to a method for the preparation of sitagliptin phosphate and sitagliptin phosphate anhydrous of Formula (I') and monohydrate of Formula (I), 

Process for the preparation of sitagliptin phosphate

The present invention provides an amorphous form of apremilast and process for preparation thereof. The present invention also provides a pharmaceutical composition comprising an amorphous apremilast and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of active psoriatic arthritis.

Amorphous form of apremilast

A stable amorphous form of dasatinib of Formula (I) wherein amorphous dasatinib after exposure to a relative humidity of 75% at 40 &#xb0; C. or 60% at 25 &#xb0; C. for a period of at least three months doesn't change to crystalline form and a process for the preparation of the amorphous form of dasatinib of Formula (I). 

Growing community of inventors

Gujarat, India

Kumar Kamlesh Singh